Trigger Site Deactivation Surgery for Headaches is Associated with Decreased Postoperative Medication Use

• Published in: Plastic and reconstructive surgery. Global open 2021-06, Vol.9 (6), p.e3634-e3634
• Main Authors: Amador, Ricardo O., Gfrerer, Lisa, Panzenbeck, Paul, Hansdorfer, Marek A., Austen, William G.
• Format: Article
• Language: English
• Subjects: Hand/Peripheral Nerve; Original
• ISSN: 2169-7574; 2169-7574
• DOI: 10.1097/GOX.0000000000003634

Patients with chronic headaches suffer debilitating pain, which often leads to the use of numerous medications. Trigger site deactivation surgery has emerged as an effective treatment for select headache patients. This study aims to describe the preoperative and postoperative medication use among patients undergoing trigger site deactivation. One-hundred sixty patients undergoing trigger site deactivation surgery between September 2012 and November 2017 were prospectively enrolled. Information on medication use, including type, dose, and frequency of use, was collected. Follow-up surveys were sent to all patients 12 months postoperatively. One-hundred twenty-nine patients met the inclusion criteria. At the time of screening, 96% of patients described taking prescription medication for their headache pain. The type of medication varied among patients but included preventative in 55%, abortive in 52%, rescue in 54%, and antiemetic in 18%. Thirty-one percent of patients reported using opioid medication for their headache pain. At 12 months postoperatively, 68% of patients reported decreased prescription medication use. Patients reported a 67% decrease in the number of days they took medication. Twenty-three percent stopped medications altogether. Fifty percent of patients reported that their migraine medication helped them more compared with preoperatively. Trigger site deactivation surgery has been associated with improvements in headache symptoms. We now show that it is also associated with a significant decrease in medication use.